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Abstract
Introduction: Epigenetic events are, along with genetic alteration, important in the development and progression
of cancer. Promoter hypermethylation causes gene silencing and is thought to be an early event in carcinogenesis.
The role of promoter hypermethylation in male breast cancer has not yet been studied.
Methods: In a group of 108 male breast cancers, the methylation status of 25 genes was studied using
methylation-specific multiplex ligation-dependent probe amplification. Methylation of more than 15% was regarded
indicative for promoter hypermethylation. Methylation status was correlated with clinicopathological features, with
patients’ outcome and with 28 female breast cancer cases.
Results: Promoter hypermethylation of the genes MSH6, WT1, PAX5, CDH13, GATA5 and PAX6 was seen in more
than 50% of the cases, but was uncommon or absent in normal male breast tissue. High overall methylation status
was correlated with high grade (P = 0.003) and was an independent predictor of poor survival (P = 0.048; hazard
ratio 2.5). ESR1 and GSTP1 hypermethylation were associated with high mitotic count (P = 0.037 and P = 0.002,
respectively) and high grade (both P = 0.001). No correlation with survival was seen for individual genes.
Compared with female breast cancers (logistic regression), promoter hypermethylation was less common in a
variety of genes, particularly ESR1 (P = 0.005), BRCA1 (P = 0.010) and BRCA2 (P < 0.001). The most frequently
hypermethylated genes (MSH6, CDH13, PAX5, PAX6 and WT1) were similar for male and female breast cancer.
Conclusion: Promoter hypermethylation is common in male breast cancer and high methylation status correlates
with aggressive phenotype and poor survival. ESR1 and GSTP1 promoter hypermethylation seem to be involved in
development and/or progression of high-grade male breast cancer. Although female and male breast cancer share
a set of commonly methylated genes, many of the studied genes are less frequently methylated in male breast
cancer, pointing towards possible differences between male and female breast carcinogenesis.
Introduction
Along with genetic alterations, epigenetic events are
important in cancer development and progression.
Hypermethylation of CpG islands in promoter regions
(further denoted methylation) is the most well charac-
terized epigenetic change and is a common mechanism
for silencing tumor suppressor genes [1]. Methylation is
reversible and therefore is an attractive therapeutic
target, and can serve as a marker for therapy response
and prognosis [2].
Methylation is very common in virtually all cancer
types but can also be a physiological event, as in genomic
imprinting [3]. Methylation is involved in the develop-
ment of female breast cancer, with frequent methylation
of PAX6, BRCA2, PAX5, WT1, CDH13 and MSH6 in
ductal carcinoma in situ and invasive ductal cancer [4].
On the contrary, methylation is less common in estrogen
receptor (ER)-negative, lymph node-negative and
BRCA1-associated female breast cancer [5]. Methylation
is thought to be an early event in carcinogenesis of
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female breast cancer, and the methylation status of speci-
fic genes may therefore be useful as a potential screening
target in clinical practice [4,6].
Most of the diagnostic and therapeutic algorithms for
male breast cancer have been extrapolated from female
breast cancer although we and others have already
demonstrated that there seem to be important differences
between the two. Male breast cancers are more often
hormone-positive while HER2-amplified and basal-like
breast cancers are rare in men [7-10]. Different genes
and mechanisms of oncogene activation also play a role
in the carcinogenesis of male breast cancer: high-level
amplification is less common, but whole chromosome
arm gains are more often seen in male breast cancer [11].
Because of its general importance in carcinogenesis,
methylation is probably also important in the develop-
ment of male breast cancer, but this has not yet been
studied.
Several techniques are available to assess methylation.
The methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA) technique allows
simultaneous evaluation of the methylation status of a
variety of genes in one PCR reaction. With this high-
throughput approach, which shows good correlations
with other methylation-specific techniques, a reliable
general view of methylation in several important tumor
suppressor genes can be obtained [12,13].
In this study we investigated the role of methylation of
several important tumor suppressor genes in male breast
cancer using MS-MLPA. We correlated methylation pat-
terns with clinicopathological features and prognosis.
The results were also compared with a group of female
breast cancers.
Materials and methods
Patients: specimens and clinical information
One hundred and ten consecutive cases of surgical breast
specimens of invasive male breast cancer from 1986 to
2010 were collected from four different pathology labora-
tories in the Netherlands (St Antonius Hospital Nieuwe-
gein, Diakonessenhuis Utrecht, University Medical Center
Utrecht and Laboratory for Pathology East Netherlands)
as described in more detail previously [10]. H & E slides
were reviewed by three experienced observers (PJvD, RK
and AHJV-M) to confirm the diagnosis and to type and
grade according to current standards.
Pathology reports were used to retrieve information on
age, tumor size and lymph node status. The mean age of
these patients was 66 years (range 32 to 89 years). The
tumor size ranged from 0.8 to 5.5 cm (average 2.2 cm).
In 86% of cases the lymph node status was known, and
55% of these patients had lymph node metastases. The
majority of cases were diagnosed (according to the
World Health Organization) as invasive ductal carcinoma
(90%). The remaining cases were lobular (n = 3), mixed
type (ductal/lobular) (n = 2), invasive cribriform (n = 1),
papillary (n = 1), mucinous (n = 2), invasive micropapil-
lary (n = 1) or adenoid cystic carcinomas (n = 1). Accord-
ing to the modified Bloom and Richardson score [14]
most tumors were grade 2 (41%) or grade 3 (36%). Mito-
tic activity was assessed as described previously [15] with
a mean mitotic index per 2 mm2 of 11 (range 0 to 56).
For all cases, the hormone receptor and HER2 status
were reassessed as described previously [10]. Tissue
microarray slides were used for immunohistochemical
stainings for ER and progesterone receptor (PR), and
chromogenic in situ hybridization for HER2 assessment.
Most tumors were ER-positive (102/110, 93%) and PR-
positive (71/110; 65%), and HER2 amplification was rare
(4/110, 4%).
In addition, normal male breast tissue was obtained
from 10 autopsies. These patients had no history of a
breast tumor. The subareolar region was resected and,
after fixation in 4% formalin, was dissected and
embedded in paraffin. From these blocks, 4 μm sections
were cut and stained for H & E; if ducts were present, the
areas richest in ducts were dissected for DNA isolation.
Anonymous use of redundant tissue for research pur-
poses is part of the standard treatment agreement with
patients in our hospital [16]. Ethical approval was not
required.
DNA extraction and MS-MLPA analysis
Representative tumor areas were identified on H & E-
stained slides and corresponding areas (at least 1 cm2)
were dissected from 8 μm paraffin slides using a scalpel.
DNA was extracted by overnight incubation in proteinase
K (10 mg/ml; Roche, Almere, the Netherlands) at 56°C.
MS-MLPA was performed according to the manufac-
turers’ instructions (MRC Holland, Amsterdam, the Neth-
erlands), using a Veriti® 96-well thermal cycler (Applied
Biosystems, Foster City, CA, USA). The ME002-B1 kit
(MRC Holland), containing 25 tumor suppressor genes
(Table 1), was used as previously [4]. Two different CpG
probes were available for the genes MGMT and RB1.
The principle of MS-MLPA has been described else-
where in more detail [17]. In short, MS-MLPA kits con-
tain probes for methylation quantification, which are
similar to those in conventional multiplex ligation-depen-
dent probe amplification except that the sequence
detected by the MS-MLPA probes contains a restriction
site for the methylation-sensitive HhaI enzyme. After
DNA denaturation and overnight incubation with the
probe mix, the samples are divided into two tubes, one of
which is incubated with HhaI. In this tube, unmethylated
DNA is digested and not exponentially amplified by PCR.
Because methylated DNA is prevented from being
digested by HhaI, these probes are ligated and therefore
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amplified by PCR. The ratio between probes incubated
with and without HhaI gives an estimation of the methy-
lation status. Appropriate negative and positive (Sssi-
methylated DNA) controls were taken along with each
MS-MLPA run. The PCR products were separated by
electrophoresis on an ABI 3730 capillary sequencer
(Applied Biosystems).
Methylation analysis was carried out with Genescan
v4.1 (Applied Biosystems) and Coffalyser v9.4 (MRC
Holland) software. Relative probe peaks were calculated
by dividing the signal of each probe by the signal of
every reference probe in one sample (intra-sample nor-
malization). For the final methylation status, the ratio of
relative probe peaks of the undigested sample (without
HhaI) and the corresponding digested sample (with
HhaI) were calculated for each probe. In case two CpG
loci were present for one gene (MGMT and RB1), the
mean methylation status was calculated for further
analysis.
A promoter methylation ratio > 0.15 (corresponding
to > 15% methylation) was regarded as indicative for
promoter hypermethylation, based on cell-line experi-
ments and previous experience [4,18]. The cumulative
methylation index (CMI) was calculated as the sum of
the methylation percentage of all genes [5].
Comparison with female breast cancer
A previously described group of female breast cancers
was used to compare promoter hypermethylation in
male and female breast cancer [4]. This group consists
of 33 patients with invasive ductal carcinoma and a
mean age of 55 years (range 32 to 81 years). The tumor
size ranged from 0.5 to 6.5 cm (average 2.1 cm). The
mean mitotic activity was 14 per 2 mm2 and, according
to the modified Bloom and Richardson score, most
tumors were grade 2 (10/33, 30%) or grade 3 (17/33,
52%). ER-positivity was common (27/31, 87%) and 71%
of the tumors were PR-positive (22/31, 71%). HER2
amplification was seen in two cases (2/31, 6%). The
same tumor suppressor kit (ME002-B1; MRC Holland)
was used.
Statistical analysis
Statistical calculations were performed using SPSS for
Windows v15.0 (SPSS Inc., Chicago, IL, USA), regarding
two-sided P < 0.05 as significant. Correlations between
Table 1 Genes in the MS-MLPA kit and frequencies of promoter hypermethylation in male breast cancer patients
Gene Hypermethylation Chromosome Gene name
MSH6 104 (96%) 02p16.3 mutS homologue 6
WT1 91 (84%) 11p13 Wilms tumor 1
PAX5 85 (79%) 09p13.2 Paired box 5
CDH13 83 (77%) 16q24.1 Cadherin 13, H-cadherin
GATA5 60 (56%) 20q13.33 GATA binding protein 5
PAX6 57 (53%) 11p13 Paired box 6
GSTP1 47 (44%) 11q13.1 Glutathione S-transferase p1
THBS1 21 (19%) 15q14 Thrombospondin 1
BRCA2 18 (17%) 13q13.1 Breast cancer gene 2
CD44 17 (16%) 11p13 CD44 molecule (Indian blood group)
TP73 14 (13%) 01p36.32 Tumor protein p73
TP53 12 (11%) 17p13.1 Tumor protein p53
ESR1 9 (8%) 06q25.1 Estrogen receptor 1
CADM1 9 (8%) 11q23.2 Cell adhesion molecule 1
MGMT 8 (7%) 10q26.3 O-6-Methylguanine-DNA methyltransferase
STK11 8 (7%) 19p13.3 Serine/threonine kinase 11
RARB 5 (5%) 03p24.2 Retinoic acid receptor beta
PTEN 5 (5%) 10q23.31 Phosphatase and tensin homologue
PYCARD 5 (5%) 16p11.2 PYD and CARD domain containing (TMS1)
RB1 3 (3%) 13q14.2 Retinoblastoma 1
BRCA1 2 (2%) 17q21.31 Breast cancer gene 1
CDKN2A 2 (2%) 09p21.3 Cyclin-dependent kinase inhibitor 2A (p14-ARF)
VHL 2 (2%) 03p25.3 von Hippel-Lindau
ATM 1 (1%) 11q22.3 Ataxia telangiectasia mutated
CHFR 1 (1%) 12q24.33 Checkpoint with forkhead and ring finger domains
Genes contained in the ME002-B1 MS-MLPA kit (MRC Holland, Amsterdam, the Netherlands) and frequencies of promoter hypermethylation (> 15%) in 108 male
breast cancer patients.
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promoter hypermethylation (> 15% methylation) and
clinicopathological characteristics were calculated with
analysis of variance for continuous variables and with
the Pearson chi-square test (or Fisher’s exact test when
appropriate) for categorical variables. The following clin-
icopathological features were dichotomized: age (> 50
years), tumor size (> 2.0 cm), mitotic count (> 8) and
histological grade (1/2 vs. 3). The Mann-Whitney test
was used to calculate differences in CMI and clinico-
pathological features. Correlation between the number
of methylated genes and clinicopathological features was
calculated with Spearman’s rho. Unsupervised hierarchi-
cal clustering using the statistical program R [19] was
performed to analyze relevant clusters and co-methyla-
tion. Absolute methylation percentages were used and
all cases with methylation < 5% were pooled together.
Logistic regression analysis was performed to compare
methylation in male and female breast cancer, taking
significant clinicopathological differences between the
two groups into account. Backward stepwise method
was used until the most predictive variables remained.
Survival data were obtained from the Integral Cancer
Registration the Netherlands (IKNL). Outcome data
were available for 101 cases with a mean follow-up of
5.7 years. Survival analysis was therefore based on
5-year survival rates. For univariate survival analysis,
Kaplan-Meier curves were plotted and analyzed with the
log-rank test. Multivariate survival analysis was per-
formed with Cox regression (enter and remove limits
0.10). The CMI and number of methylated genes were
dichotomized for survival analysis according to the most
predictive threshold.
Results
Methylation status by MS-MLPA
In two male breast cancer cases the amount of DNA
was insufficient, leaving 108 cases for further analysis.
The methylation status of the 25 analyzed tumor sup-
pressor genes is presented in Table 1. All cases except
one showed methylation (15% cutoff) of at least one
gene, with an average of six genes (range 0 to 26).
Methylation was very common for MSH6 (96%), WT1
(83%), PAX5 (79%) and CDH13 (77%). On the contrary,
methylation was very rare in RB1 (3%), BRCA1 (2%),
CDKN2A (2%), VHL (2%), ATM (1%) and CHFR (1%).
The mean CMI was 364 (range 129 to 904).
In male breast tissue derived from autopsies, gyneco-
mastia was seen in three cases. The other seven cases
harbored normal male breast ducts. Methylation was
seen in the genes MSH6 (4/10, 40%), ESR1 (2/10, 20%),
PAX5 (1/10, 10%) and CDH13 (1/10, 10%). No methyla-
tion was found in all of the other genes. The mean CMI
in these cases was also low at 16 (range 11 to 27).
Correlation with clinicopathological features
Higher CMI was correlated with high mitotic count (P =
0.046) and high grade (P = 0.003). The number of methy-
lated genes was significantly higher in grade 3 cancers
(P = 0.034), and correlated with a high mean mitotic
count (P = 0.021). Two individual genes were associated
with a more aggressive phenotype: the mean mitotic
count was higher in tumors with ESR1 (10 vs. 16; P =
0.037) and GSTP1 (8 vs. 14; P = 0.002) methylation. Both
genes were also associated with high grade (both P =
0.001). For ESR1 eight out of nine methylated tumors
were grade 3, and for GSTP1 25 out of 47 methylated
tumors were grade 3. Finally, tumors with MGMT
methylation had a mean tumor size of 3.2 cm, which was
significantly larger compared with tumors without
MGMT methylation (2.1 cm; P = 0.002). No association
was seen between any genes on the one hand and age,
lymph node, PR and HER2 status on the other.
Cluster analysis
Hierarchical cluster analysis revealed three groups of
clustered genes (Figure 1). One group consisted of the
genes WT1, CDH13, MSH6, PAX5, GSTP1, GATA5 and
PAX6, seven genes in which methylation was very com-
mon. Indeed, in 15% of cases all these genes showed
methylation. The second cluster was formed by genes
with intermediate methylation rates (5 to 19%). In the
third group the remaining genes clustered together.
Methylation was rare (< 8%) in these genes. Regarding all
of the patients, male breast cancer cases were not divided
into clear distinctive clusters. At least four different
groups could be identified and these clusters displayed
no distinct clinicopathological features. One case did not
fit into any of the groups. This grade 3 male breast can-
cer case showed a high methylation ratio in nearly all
genes.
Comparison with female breast cancer
Because breast cancer is a heterogeneous disease, only
luminal-type male breast cancer and luminal-type female
breast cancer (defined by ER and/or PR expression) were
compared. In this approach, age was the only clinicopatho-
logical feature that was significantly different between the
two groups. Male breast cancer patients were significantly
older (66 years vs. 54 years; P < 0.001).
Figure 2 illustrates the methylation status of the 25 stu-
died genes in luminal-type male (n = 95) and luminal-type
female (n = 28) breast cancer. Methylation was much less
frequent in male breast cancer in a variety of genes. Parti-
cularly, ESR1, BRCA1 and BRCA2 were less often methy-
lated compared with female breast cancer and were strong
independent predictors of gender in logistic regression
analysis (P = 0.005, P = 0.010 and P < 0.001, respectively).
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The genes CD44 (P = 0.050), RARB (P = 0.026), ATM (P =
0.017) and STK11 (P = 0.040) also showed less frequent
methylation in male breast cancer. On the other hand, the
high frequency of methylation in MSH6, PAX5, PAX6 and
CDH13 was shared between male and female breast
cancer.
Only age was taken into account during logistic
regression analysis using gender as the determinant,
because no other clinicopathological feature was signifi-
cantly different between the two groups. When leaving
out age and using the Pearson chi-square test, methyla-
tion in PTEN and VHL was also significantly less com-
mon in male breast cancer (P = 0.029 and P = 0.025,
respectively). None of the studied genes was more fre-
quently methylated in male breast cancer.
Survival analysis
Grade 3 (P = 0.027), high mitotic count (> 8; P = 0.015)
and large tumor size (> 2.0 cm; P = 0.036) were corre-
lated with decreased 5-year survival as expected. No
individual methylated gene was significantly correlated
with patients’ outcome, although tumors with GATA5
methylation showed a trend towards decreased 5-year
survival (64% vs. 82%; P = 0.083). When the number of
methylated genes was dichotomized using a threshold of
six methylated genes, however, the group with six or
more methylated genes had significantly decreased sur-
vival compared with tumors with less than six methy-
lated genes (P = 0.022; Figure 3), but was not a
significant independent prognostic factor in Cox regres-
sion (P = 0.057). Tumors with high CMI (> 350) also
had decreased survival (P = 0.033; Figure 3) and high
CMI was an independent prognosticator in Cox regres-
sion (P = 0.048; hazard ratio 2.5).
Discussion
Promoter hypermethylation is an important gene-silen-
cing mechanism thought to be an early event in carcino-
genesis [1]. Understanding the epigenetic role in male
breast cancer is important to gain further insight into
male breast carcinogenesis and for the identification of
potential biomarkers for diagnosis and treatment [20,21].
Epigenetic changes in male breast cancer had not yet
been studied and therefore we investigated promoter
hypermethylation in a large group of 108 patients with
this rare disease using the high-throughput MS-MLPA
Figure 1 Hierarchical clustering analysis of male breast cancer patients. Unsupervised hierarchical clustering of absolute methylation
percentages in 25 genes in 108 male breast cancer patients. One gene cluster consisted of WT1, CDH13, MSH6, PAX5, GSTP1, GATA5 and PAX6,
seven genes in which methylation was very common. The second cluster was formed by genes with intermediate methylation rates (5 to 19%),
and in the third cluster the remaining genes with little methylation (< 8%) grouped together. No clear distinctive clusters of male breast cancer
cases were found.
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approach, enabling evaluation of the methylation status
of a variety of genes in one PCR.
Not surprisingly, methylation does occur in male breast
cancer. The genes MSH6, WT1, PAX5, CDH13, GATA5
and PAX6 showed promoter hypermethylation in more
than 50% of cases, indicating that these genes are prob-
ably often involved in male breast carcinogenesis. These
genes are required for normal development of several
organ systems and/or play a role in DNA repair, cell
adhesion, cell growth and migration, although the func-
tion of some of these genes is still poorly understood
[22-26]. Loss of function of both alleles leads to complete
knockdown of these genes, which may facilitate malig-
nant transformation. Methylation, with aberrant silencing
of one of these alleles, could be the initiating event, the
second hit or both [27]. MSH6 methylation was also
Figure 2 Methylation status of the 25 studied genes in luminal-type breast cancer. Promoter hypermethylation (> 15% methylation) of the
25 studied genes in luminal-type male (n = 95) and luminal-type female (n = 28) breast cancer.
Figure 3 Five-year survival according to number of methylated genes and cumulative methylation index. Five-year survival with
corresponding P values (log rank) according to high number of methylated genes (≥ 6) and high cumulative methylation index (CMI > 350).
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quite common in the normal male breast, although at a
lower frequency than our group of male breast cancer
cases. The other commonly methylated genes in male
breast cancer were not found to be methylated in our 10
cases of normal male breast tissue, confirming the impor-
tant role of methylation in the development of male
breast cancer.
In male breast cancer, methylation was very rare in
BRCA1, CDKN2A, VHL, ATM and CHFR (< 2%) - indi-
cating that methylation of these genes does not seem to
play a prominent role in male breast carcinogenesis.
Male breast cancer with an aggressive phenotype har-
bored an increased number of methylated genes and had
a higher CMI. In addition, tumors with six or more
methylated genes or high CMI had a worse outcome.
High CMI was even an independent predictor of poor
survival when corrected for grade, mitotic count and
tumor size. This indicates that accumulation of methy-
lated genes and an overall higher methylation status
seem to be important in the development of more
aggressive male breast cancer with poor survival. The
hallmark of high-grade breast cancer is genetic instability
[28], which in male breast cancer seems to include accu-
mulation of methylated genes. A similar trend was noted
in female breast cancer, and female breast cancer patients
with an increasing number of methylated genes also have
an unfavorable outcome [4,29,30].
Two single genes were identified in which methylation
was correlated with high mitotic count and high grade:
ESR1 and GSTP1. High-grade breast cancer is believed to
arise from high-grade precursor lesions by gaining differ-
ent genetic and epigenetic changes compared with low-
grade breast cancer [31,32]. ESR1 and GSTP1 methylation
could be important in the development of these high-
grade male breast cancers. GSTP1 belongs to a family of
metabolic enzymes and is involved in the detoxification of
carcinogens and chemotherapeutic agents by conjugating
them with glutathione [33]. In female breast cancer,
GSTP1 hypermethylation is correlated with high-grade
ductal carcinoma in situ and high-grade invasive breast
cancer, presence of lymph node metastasis and poor out-
come [4,30,34,35]. ER, encoded by ESR1, is an important
factor in breast cancer, because studies in females have
shown that patients with hormone-negative tumors do not
benefit from endocrine therapy [36]. In the present study
we could not demonstrate a relation between ESR1 methy-
lation and ER expression, although this needs to be inter-
preted with caution since only seven out of 108 cases were
ER-negative in the present study. Another recent study
also concluded that the relation between ESR1 methyla-
tion and protein expression is weak and unlikely to repre-
sent a predominant mechanism of ER silencing [37].
There was also no relation between methylation and
expression of TWIST as shown by us, so this may not be
unusual [38]. Larger series of ER-negative male breast can-
cer cases will be needed to further explore this relation-
ship. Similar to female breast cancer, methylation of ESR1
seems to be a biomarker for high malignant male breast
cancer. Indeed, in female breast cancer ESR1 promoter
hypermethylation has been correlated with poor prognosis
[39]. ESR1 methylation and GSTP1 methylation were not
significantly correlated with poor survival in our group of
male breast cancer and therefore do not seem to be useful
prognostic biomarkers in male breast cancer.
Compared with female breast cancer, methylation was
less common in male breast cancer in several of the stu-
died genes, particularly ESR1, BRCA1 and BRCA2.
BRCA1 and BRCA2 promoter hypermethylation was
encountered in, respectively, 2% and 18% of the male
breast cancers, but was seen in 18% and 64% of the
female breast cancers, using the same approach and simi-
lar cutoff criteria. These results points towards possible
important differences between female and male breast
carcinogenesis with regard to methylation. BRCA1
methylation is more common in relatively young, preme-
nopausal women [40], which could explain the higher
incidence in female breast cancer since the male breast
cancer patients were significantly older than the female
breast cancer patients. However, in the present study we
corrected for age in logistic regression, so gender-specific
differences also seem to play a role here. Differences in
genetic predisposition may also influence the epigenetic
profile of these tumors and could be responsible for
some of the differences found in promoter hypermethyla-
tion between male and female breast cancer. Approxi-
mately 10% of men with breast cancer are known to have
a genetic predisposition, and especially BRCA2 mutations
seem to be important [41]. Unfortunately no data regard-
ing BRCA germline mutations were available for both
cohorts, but it seems probable that there is a higher rate
of hidden BRCA2 mutation carriers in the male breast
cancer group. This higher rate of BRCA2 mutation car-
riers may well explain the lower rate of BRCA2 promoter
hypermethylation in the male breast cancer group com-
pared with female breast cancers [42]. Interestingly,
genes with frequent methylation in male breast cancer
(MSH6, CDH13, PAX5, PAX6 and WT1) were also very
commonly methylated in female breast cancer.
The methylation status of both groups was obtained
using the same technique. However, the male breast
cancer cases were microdissected by a scalpel and the
female breast cancer cases by laser microdissection.
Although the latter method is more precise we do not
think this may have influenced our results. The male
breast cancer tumors were quite large and rich in tumor
cells and could therefore be well harvested for DNA
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isolation based on scalpel dissection. Besides, multiplex
ligation-dependent probe amplification is relatively
insensitive to tumor cell content [43].
Conclusion
Methylation seems to be important in the development
of male breast cancer. More than 50% of the tumors
showed methylation in MSH6, WT1, PAX5, CDH13,
GATA5 and PAX6. The accumulation of methylated
genes and an overall high methylation status was corre-
lated with a more aggressive phenotype and poor survi-
val. ESR1 and GSTP1 were the only single genes
associated with mitotically active and high-grade male
breast cancers. Compared with female breast cancer,
methylation occurred less often in male breast cancer.
On the other hand, the most frequently methylated
genes were shared between male and female breast can-
cer. Our results point towards differences in carcinogen-
esis between male and female breast cancer, hidden
behind similarities.
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